

CONTENTS

List of Contributors

Preface to Second Edition

Preface First Edition

1 Chemistry of Reactive Species

Frederick A. Villamena

- 1.1 Redox Chemistry, 1
- 1.2 Classification of Reactive Species, 2
 - 1.2.1 Type of Orbitals, 3
 - 1.2.2 Stability of Radicals, 3
 - 1.2.3 Reactive (O, N, S, X) Species, 4
- 1.3 Reactive Oxygen Species, 4
 - 1.3.1 Oxygen Molecule (O_2 , Triplet Oxygen, Dioxygen), 4
 - 1.3.2 Superoxide Radical Anion ($O_2^{\bullet-}$), 6
 - 1.3.2.1 Dismutation Reaction, 6
 - 1.3.2.2 Nucleophilic Substitution Reaction, 8
 - 1.3.2.3 Addition Reactions, 8
 - 1.3.2.4 Proton-radical Transfer, 8
 - 1.3.2.5 Reaction with Iron-Sulfur [Fe-S] Cluster, 9
 - 1.3.3 Hydroperoxyl Radical ($HO_2^{\bullet}$), 9
 - 1.3.4 Hydrogen Peroxide (H_2O_2), 10
 - 1.3.5 Hydroxyl Radical ($HO^{\bullet}$), 11
 - 1.3.5.1 Reactivity with Ions, 12
 - 1.3.5.2 Modes of Reaction with Organic Molecules, 12
 - 1.3.6 Singlet Oxygen (1O_2 , $^1\Delta_g$ or $^1O_2^*$), 14
- 1.4 Reactive Nitrogen Species, 15
 - 1.4.1 Nitric Oxide (NO or $NO^{\bullet}$), 15
 - 1.4.1.1 $NO^{\bullet}$ Radical Reaction, 15
 - 1.4.1.2 $NO^{\bullet}$ -metal Reaction, 16
 - 1.4.2 Nitrogen Dioxide ($NO_2^{\bullet}$), 16
 - 1.4.2.1 Addition to Double Bonds, 17
 - 1.4.2.2 Radical-radical Addition, 17

1.4.2.3	Reaction with Thiols, 17
1.4.3	Peroxynitrite (ONOO ⁻), 17
1.5	Reactive Sulfur and Chlorine Species, 18
1.5.1	Thiyl or Sulfhydryl Radical (RS [•]), 18
1.5.2	Disulfide (RSSR), 20
1.5.3	Hypochlorous Acid (HOCl), 20
1.6	Reactivity, 23
1.6.1	Thermodynamic Consideration, 23
1.6.2	Kinetic Consideration, 25
1.6.2.1	Unimolecular or First-order Reactions, 25
1.6.2.2	Bimolecular or Second-order Reactions, 26
1.6.2.3	Transition State Theory, Reaction Coordinates, and Activation Energies, 26
1.7	Origins of Reactive Species, 27
1.7.1	Biological Sources, 27
1.7.1.1	NADPH Oxidase, 27
1.7.1.2	Xanthine Oxidoreductase or Oxidase, 28
1.7.1.3	Mitochondrial Electron Transport Chain (METC), 28
1.7.1.4	Hemoglobin (Hb), 28
1.7.1.5	Nitric Oxide Synthases, 28
1.7.1.6	Cytochrome P450 (CYP), 29
1.7.1.7	Cyclooxygenase (COX) and Lipoxygenase (LPO), 29
1.7.1.8	Endoplasmic Reticulum (ER), 30
1.7.2	Non-biochemical Sources, 30
1.7.2.1	Photolytic, 30
1.7.2.2	Sonochemical, 30
1.7.2.3	Photochemical, 30
1.7.2.4	Electrochemical, 31
1.7.2.5	Chemical, 31
1.8	Methods of Detection, 32
1.8.1	In Vitro, 32
1.8.1.1	Fluorescence and Chemiluminescence, 32
1.8.1.2	UV-Vis Spectrophotometry and HPLC, 34
1.8.1.3	Immunochemical, 34
1.8.1.4	Electron Paramagnetic Resonance (EPR) Spectroscopy, 35
1.8.2	In Vivo, 38
1.8.2.1	Histochemical, 38
1.8.2.2	Immunocytochemical Methods, 38
1.8.2.3	Low-frequency EPR Imaging, 38
1.8.2.4	In Vivo Spin Trapping-Ex vivo EPR Measurement, 38
1.8.2.5	Immuno-spin Trapping, 38
	References, 39

2 Lipid Peroxidation and Nitration

49

Sean S. Davies and Lili Guo

Overview, 49

2.1 Peroxidation of PUFAs, 49

- 2.1.1 Hydroperoxy Fatty Acid Isomers (HpETEs and HpODEs), 50
- 2.1.2 Hydroxy Fatty Acids (HETEs and HODEs), 51
- 2.1.3 Isoleukotrienes, 51
- 2.1.4 Epoxy Alcohols, 52

- 2.2 Cyclic Endoperoxides and Their Products, 52**
 - 2.2.1 Isoprostanes, 52**
 - 2.2.1.1 Isoprostane Regio- and Stereoisomers, 54
 - 2.2.1.2 F₂-Isoprostanes, 54
 - 2.2.1.3 Other Major Isoprostane Products, 54
 - 2.2.1.4 Minor Isoprostane Products, 56
 - 2.2.2 Diepoxide Pathway Products, 57
 - 2.2.2.1 Isofurans and Related Compounds, 57
 - 2.2.3 Serial Cyclic Endoperoxides, 57
- 2.3 Fragmented Products of Lipid Peroxidation, 58**
 - 2.3.1 Short-Chain Alkanes, Aldehydes, and Acids, 58
 - 2.3.2 Oxidatively Fragmented Phospholipids, 58
 - 2.3.3 PAF Acetylhydrolase, 59
 - 2.3.4 Hydroxyalkenals, 59
 - 2.3.5 Malondialdehyde, 61
 - 2.3.6 Acrolein, 61
- 2.4 Epoxy Fatty Acids, 62**
- 2.5 Lipid Nitrosylation, 62**
 - 2.5.1 Formation of Reactive Nitrogen Species, 63
 - 2.5.2 Lipid Nitration Reactions, 63
 - 2.5.3 Detection of Lipid Nitration *In Vivo*, 64
 - 2.5.4 Bioactivities of Nitrated Lipids, 64
- Summary, 65
- References, 65

3 Protein Posttranslational Modification

71

James L. Hougland, Joseph Darling, and Susan Flynn

Overview, 71

- 3.1 Oxidative Stress-Related PTMs: Oxidation Reactions, 71**
 - 3.1.1 Cysteine, 71**
 - 3.1.1.1 Formation of Sulfur–Oxygen Adducts: Sulfenic, Sulfenic, and Sulfonic Acids, 72
 - 3.1.1.2 Formation of Sulfur–Nitrogen Adducts: S-Nitrosothiols and Sulfonamides, 73
 - 3.1.1.3 Formation of Sulfur–Sulfur Adducts: Disulfides and S-Glutathionylation, 74
 - 3.1.1.4 Redoxins: Enzymes Catalyzing Cysteine Reduction, 75
 - 3.1.2 Methionine, 76
 - 3.1.3 Oxidation of Aromatic Amino Acids, 78
 - 3.1.3.1 Tyrosine, 78
 - 3.1.3.2 Tryptophan, 79
 - 3.1.3.3 Histidine, 79
 - 3.1.3.4 Phenylalanine, 79
 - 3.1.4 Oxidation of Aliphatic Amino Acids, 79
- 3.2 Amino Acid Modification by Oxidation-Produced Electrophiles, 80**
 - 3.2.1 Electrophiles Formed by Oxidative Stress, 80
 - 3.2.2 Carbonylation Reactions with Amino Acids, 80
- 3.3 Detection of Oxidative-Stress Related PTMs, 81**
 - 3.3.1 Mass Spectrometry, 81
 - 3.3.2 Chemoselective Functionalization, 82
 - 3.3.3 Cysteine Modifications, 82
 - 3.3.3.1 Sulfenic Acids, 82
 - 3.3.3.2 Cysteine-Nitrosothiols, 82

- 3.3.3.3 Cysteine-Glutathionylation, 82
- 3.3.4 Protein Carbonylation, 83
- 3.4 Role of PTMs in Cellular Redox Signaling, 84
- Summary, 85
- References, 85

4 DNA Oxidation

93

Dessaegn B. Nemera, Amy R. Jones, and Edward J. Merino

Overview, 93

- 4.1 The Context of Cellular DNA Oxidation, 93
- 4.2 Oxidation of Oligonucleotides, 94
- 4.3 Examination of Specific Oxidative Lesions, 96
 - 4.3.1 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine, 96
 - 4.3.2 Lesions on Ribose Bases Including Apurinic or Apyrimidinic Sites, 99
 - 4.3.3 Novel Types of Ribose and Guanine Oxidative Lesions and Future Outlook, 101
 - 4.3.3.1 Tandem Lesions, 101
 - 4.3.3.2 Hyperoxidized Guanine, 102
 - 4.3.3.3 Oxidative Cross-Links, 103
- Future Outlook of DNA Oxidative Lesions, 103
- References, 103

5 Cellular Antioxidants and Phase 2 Proteins

113

Yunbo Li

- 5.1 Definitions, 113
 - 5.1.1 Antioxidants, 113
 - 5.1.2 Phase 2 Proteins, 113
- 5.2 Roles in Oxidative Stress, 113
 - 5.2.1 Superoxide Dismutase, 113
 - 5.2.2 Catalase, 114
 - 5.2.3 Glutathione System, 114
 - 5.2.3.1 GSH and Its Synthesizing Enzymes, 114
 - 5.2.3.2 Glutathione Peroxidase, 114
 - 5.2.3.3 Glutathione Reductase, 115
 - 5.2.3.4 Glutathione S-Transferase, 115
 - 5.2.3.5 Glutaredoxin, 115
 - 5.2.4 Thioredoxin System, 116
 - 5.2.4.1 Thioredoxin, 116
 - 5.2.4.2 Peroxiredoxin, 116
 - 5.2.4.3 Thioredoxin Reductase, 116
 - 5.2.4.4 Sulfiredoxin, 116
 - 5.2.5 Other Antioxidants and Phase 2 Proteins, 116
 - 5.2.5.1 Heme Oxygenase, 116
 - 5.2.5.2 Methionine Sulfoxide Reductase, 117
 - 5.2.5.3 NAD(P)H:Quinone Oxidoreductase, 117
- 5.3 Molecular Regulation, 117
 - 5.3.1 General Consideration, 117
 - 5.3.2 Nrf2 Signaling, 117
 - 5.3.3 Other Regulators, 119

5.4 Induction in Chemoprevention, 119

5.4.1 Chemical Inducers, 119

5.4.2 Chemoprotection, 119

5.5 Inactivation, 119

5.5.1 Selective Chemical Inhibitors, 119

5.5.1.1 *N,N*-Diethyldithiocarbamate, 119

5.5.1.2 3-Amino-1,2,4-Triazole, 119

5.5.1.3 Buthionine Sulfoximine, 120

5.5.1.4 Sulfasalazine, 120

5.5.1.5 Dicumarol, 120

5.5.2 Drugs and Environmental Toxic Agents, 120

5.6 Conclusions and Perspectives, 121

References, 121

6 Mitochondrial Dysfunction

Yeong-Renn Chen and Chwen-Lin Chen

6.1 Mitochondria and Submitochondrial Particles, 129

6.2 Energy Transduction, 131

6.3 Mitochondrial Stress, 132

6.4 Superoxide Anion Radical Generation as Mediated by ΔPH , $\Delta\psi$, ETC, and Disease Pathogenesis, 133

6.4.1 Mediation of $\text{O}_2^{\bullet-}$ Generation by Complex I, 133

6.4.1.1 The Role of FMN Moiety, 134

6.4.1.2 The Role of Ubiquinone-Binding Domain, 134

6.4.1.3 The Role of Iron-Sulfur Clusters, 134

6.4.1.4 The Role of Cysteinyll Redox Domains, 135

6.4.1.5 Protein Cysteine Sulfonation of Complex I Mediates Myocardial Ischemia and Reperfusion Injury, 135

6.4.1.6 Complex I, Free Radicals, and Parkinsonism, 136

6.4.2 Mediation of $\text{O}_2^{\bullet-}$ Generation by Complex II, 137

6.4.2.1 The Role of FAD Moiety, 137

6.4.2.2 The Role of Ubiquinone-Binding Site, 137

6.4.2.3 Mutations of Complex II Are Related with Mitochondrial Diseases 137

6.4.2.4 Mitochondrial Complex II in the Post-ischemic Heart, 138

6.4.3 Mediation of $\text{O}_2^{\bullet-}$ Generation by Complex III, 138

6.4.3.1 The Q-Cycle Mediated by Complex III, 138

6.4.3.2 Role of Q Cycle in $\text{O}_2^{\bullet-}$ Generation, 139

6.4.3.3 The Role of Cytochrome b_L in $\text{O}_2^{\bullet-}$ Generation, 139

6.4.3.4 Bidirectionality of Superoxide Release as Mediated by Complex III, 139

6.4.3.5 Heme Damage and Protein Cysteine Sulfonation of Complex III Mediates Myocardial Ischemia and Reperfusion Injury, 139

6.4.4 Complex IV, 141

6.4.5 Aconitase Is a Source of Hydroxyl Radical, 142

6.4 Summary, 142

References, 143

7 NADPH Oxidases: Structure and Function

147

Mark T. Quinn

Overview, 147

7.1 Introduction, 147

7.2 Phagocyte NADPH Oxidase Structure, 147

7.2.1 Flavocytochrome b, 148

7.2.2 p47^{phox}, 149

7.2.3 p67^{phox}, 150

7.2.4 p40^{phox}, 151

7.2.5 Rac1/2, 151

7.2.6 Rap1A, 152

7.3 Phagocyte ROS Production, 152

7.3.1 Superoxide Anion ($O_2^{\bullet-}$), 152

7.3.2 Hydrogen Peroxide (H_2O_2), 153

7.3.3 Hypochlorous Acid (HOCl), 153

7.3.4 Hydroxyl Radical ($HO^{\bullet}$), 153

7.3.5 Singlet Oxygen ($^1O_2^*$), 154

7.3.6 Nitric Oxide ($^{\bullet}NO$) and Peroxynitrite ($OONO^-$), 154

7.4 Phagocyte NADPH Oxidase Function, 155

7.5 Nonphagocyte NADPH Oxidase Structure, 156

7.5.1 NOX1, 157

7.5.2 NOX3, 159

7.5.3 NOX4, 159

7.5.4 NOX5, 160

7.5.5 DUOX1 and DUOX2, 160

7.5.6 NOXO1, 160

7.5.7 NOXA1, 161

7.6 Nonphagocyte ROS Production, 161

7.7 Functions of Nonphagocyte NADPH Oxidases, 162

7.7.1 Cardiovascular System, 162

7.7.2 Renal System, 164

7.7.3 Pulmonary System, 165

7.7.4 Central Nervous System, 166

7.7.5 Gastrointestinal System, 167

7.7.6 Hepatic System, 168

7.7.7 Thyroid Gland, 169

Summary, 169

Acknowledgments, 169

References, 170

8 Cell Signaling and Transcription

189

Imran Rehmani, Fange Liu, and Aimin Liu

Overview, 189

8.1 Common Mechanisms of Redox Signaling, 189

8.2 Redox and Oxygen-Sensitive Transcription Factors in Prokaryotes, 191

8.2.1 Fe-S Cluster Proteins, 191

8.2.2 Prokaryotic Hydrogen Peroxide Sensors: Proteins

Utilizing Reactive Thiols, 192

8.2.3 PerR: A Unique Metalloprotein Sensor of Hydrogen Peroxide, 192

8.2.4 Summary, 194

8.3 Redox Signaling in Metazoans, 195

8.3.1 Primary Sources of ROS in Eukaryotic Redox Signaling, 195

- 8.3.2 The Floodgate Hypothesis, 196
- 8.3.3 Redox Regulation of Kinase and Phosphatase Activity, 197
- 8.3.4 Communication between ROS and Calcium Signaling, 198
- 8.3.5 Redox Modulation of Transcription Factors, 198
- 8.3.6 Summary, 199
- 8.4 Oxygen Sensing in Metazoans, 200**
 - 8.4.1 HIF, 200
 - 8.4.2 PHD Enzymes, 200
 - 8.4.3 FIH, 201
 - 8.4.4 Factors Influencing Fe(II)/ α -KG Dependent Enzymes, 202
 - 8.4.5 ROS and Oxygen Sensing, 203
 - 8.4.6 Summary, 203
- 8.5 Medical Significance of Redox and Oxygen-Sensing Pathways, 204**
 - 8.5.1 Cancer, 204
 - 8.5.2 Vascular Pathophysiology, 204
- Concluding Remarks, 205**
- References, 205**

9 Oxidative Stress and Redox Signaling in Carcinogenesis 213

*Rodrigo Franco, Aracely Garcia-Garcia, Thomas B. Kryston,
Alexandros G. Georgakilas, Mihalios I. Panayiotidis, and Aglaia Pappa*

Overview, 213

- 9.1 Redox Environment and Cancer, 213**
 - 9.1.1 Pro-Oxidant Environment and Endogenous Sources of RS in Cancer, 213**
 - 9.1.1.1 Reactive Oxygen Species (ROS)-Generating NADPH Oxidases and Cancer, 213
 - 9.1.1.2 Mitochondria Mutations, Oxidative Stress, and Cancer, 215
 - 9.1.1.3 Nitric Oxide Synthases (NOS) and Cancer, 215
 - 9.1.1.4 Other Sources of RS in Cancer, 215
 - 9.1.2 Alterations in Antioxidant Systems and Cancer, 215**
 - 9.1.2.1 Glutathione (GSH) and Glutathione-Dependent Enzymes in Cancer, 215
 - 9.1.2.2 Catalase, 216
 - 9.1.2.3 Superoxide Dismutases (SODs), 216
 - 9.1.2.4 Peroxiredoxins (PRDXs), 217
 - 9.1.2.5 Heme Oxygenase (HO), 217
 - 9.1.2.6 TRX/TRX Reductase System, 217
- 9.2 Oxidative Modifications to Biomolecules and Carcinogenesis, 217**
 - 9.2.1 Oxidative Posttranslational Protein Modifications in Cancer, 218**
 - 9.2.1.1 Protein Carbonylation, 218
 - 9.2.1.2 Protein Nitration, 218
 - 9.2.1.3 Protein Nitrosylation or Nitrosation, 218
 - 9.2.1.4 Protein Glutathionylation, 218
 - 9.2.1.5 Methionine Sulfoxide, 218
 - 9.2.2 Lipid Peroxidation (LPO) and Cancer, 219**
 - 9.2.3 Oxidative DNA Damage and Carcinogenesis, 219**
 - 9.2.3.1 Types of Oxidatively Induced DNA Damage, 219
 - 9.2.3.2 Base and Nucleotide Excision Repair in Oxidative DNA Damage Processing, 221

9.3	Measurement of Oxidative DNA Damage in Human Cancer, 223	8.3.2
9.4	Epigenetic Involvement in Oxidative Stress-Induced Carcinogenesis, 223	8.3.3
9.5	Deregulation of Cell Death Pathways by Oxidative Stress in Cancer Progression, 226	8.3.4
9.5.1	Apoptosis, 226	8.3.5
9.5.2	Autophagy, 229	8.3.6
9.5.3	Redox Regulation of Drug Resistance in Cancer Cells, 229	8.4
	Conclusions and Perspective, 230	8.4.1
	Acknowledgments, 231	8.4.2
	References, 231	8.4.3

10 Neurodegeneration from Drugs and Aging-Derived Free Radicals 247

Annmarie Ramkissoon, Aaron M. Shapiro, Margaret M. Loniewska, and Peter G. Wells

Overview, 247

10.1 ROS Formation, 247

10.1.1 Introduction to ROS, 247

10.1.2 CNS Sources of ROS, 248

10.1.2.1 Mitochondria, 248

10.1.2.2 Nicotinamide Adenine Dinucleotide Phosphate Hydrogen (NADPH) Oxidase (NOX), 249

10.1.2.3 Phospholipase A2 (PLA2), 249

10.1.2.4 Nitric Oxide Synthases (NOSs), 250

10.1.2.5 Monoamine Oxidase (MAO), 250

10.1.2.6 Cytochromes P450 (CYPs), 250

10.1.2.7 Xanthine Oxidoreductase, 250

10.1.2.8 Excitotoxicity, 251

10.1.2.9 Immune Response Microglia, 251

10.1.3 Prostaglandin H Synthases (PHSs), 251

10.1.3.1 Role of Prostaglandin Synthesis and Their Receptors, 251

10.1.3.2 Genetics of PHS, 253

10.1.3.3 Primary Protein Structures of PHSs, 256

10.1.3.4 PHS Enzymology, 257

10.1.3.5 Inhibition of PHSs, 258

10.1.3.6 Cellular Localization and CNS Expression of PHSs, 259

10.1.3.7 PHS in ROS Generation, Aging, and Neurotoxicity, 260

10.1.3.8 PHS in Neurodegenerative Diseases, 263

10.1.4 Amphetamines, 265

10.1.4.1 History and Uses, 265

10.1.4.2 Pharmacokinetics, 266

10.1.4.3 Distribution, 267

10.1.4.4 Metabolism by Cytochromes P450 (CYPs) and Elimination, 267

10.1.4.5 Receptor-Mediated Pharmacological Actions of METH, 269

10.1.4.6 Effects of METH Abuse, 270

10.1.4.7 Evidence from Animal and Human Studies for Neurotoxicity, 271

10.2 Protection against ROS, 273

10.2.1	Blood Brain Barrier (BBB), 273
10.2.2	Antioxidative Enzymes and Antioxidants, 273
10.2.2.1	Glucose-6-Phosphate Dehydrogenase (G6PD), 273
10.2.2.2	SOD, 276
10.2.2.3	H ₂ O ₂ Detoxifying Enzymes, 276
10.2.2.4	Heat Shock Proteins, 277
10.2.2.5	NAD(P)H: Quinone Oxidoreductase, 277
10.2.2.6	GSH, 277
10.2.2.7	Dietary Antioxidants in the Brain, 278
10.2.3	DNA Repair, 278
10.2.3.1	Ataxia Telangiectasia Mutated (ATM), 278
10.2.3.2	Oxoguanine Glycosylase 1 (Ogg1), 278
10.2.3.3	Cockayne Syndrome B (CSB), 279
10.2.3.4	Breast Cancer 1 (Brca1), 279
10.3	Nrf2 Regulation of Protective Responses, 279
10.3.1	Overview, 279
10.3.2	Mechanism of Action of Nrf2, 279
10.3.3	Genetics of Nrf2, 280
10.3.4	Protein Structure of Nrf2, 281
10.3.5	Regulators of Nrf2, 282
10.3.5.1	Negative Regulation by Kelch-Like ECH-Associated Protein 1 (Keap1), 282
10.3.5.2	Negative Regulation by Proteasomal Degradation, 282
10.3.5.3	Regulation of Transcriptional Complex in Nucleus, 284
10.3.6	ARE, 284
10.3.7	Activators of Nrf2, 286
10.3.8	Nrf2 in Neurotoxicity and CNS Diseases, 287
10.3.8.1	Nrf2 Expression, 287
10.3.8.2	Nrf2 in Neurodegenerative Diseases, 287
10.3.8.3	Nrf2 in Chemically Initiated Neurotoxicities, 288
10.3.8.4	Nrf2 in Fetal Neurodevelopmental Deficits, 289
10.3.9	Nrf KO Mouse Models, 290
10.3.10	Evidence for Polymorphisms in the Keap1-Nrf2-ARE Pathway, 290
	Summary and Conclusions, 291
	Acknowledgments, 291
	References, 291

11 Cardiac Ischemia and Reperfusion 321

Murugesan Velayutham and Jay L. Zweier

Overview, 321

11.1 Oxygen in the Heart, 321

11.1.1 Beneficial and Deleterious Effects of Oxygen in the Heart, 321

11.1.2 Ischemia and Reperfusion, 321

11.1.3 Oxidative Stress and Injury, 322

11.2 Sources of ROS during Ischemia and Reperfusion, 322

11.2.1 Cellular Organelles, 322

11.2.1.1	Mitochondria, 322	10.2.1	Blood Brain Barrier (BBB) 323
11.2.1.2	Endoplasmic Reticulum (ER), 322	10.2.2	Antioxidant Enzymes and Antioxidants
11.2.1.3	Peroxisomes, 323	10.2.3	Glucose-6-Phosphate Dehydrogenase (G6PD) 323
11.2.2	Cellular Enzymes, 323	10.2.4	SOD, 323
11.2.2.1	Xanthine Oxidoreductase (XOR), 323	10.2.5	H ₂ O ₂ Detoxifying Enzymes
11.2.2.2	Aldehyde Oxidase (AO), 324	10.2.6	Heat Shock Protein 323
11.2.2.3	NADPH Oxidase (Nox), 324	10.2.7	NAD(P)H:Quinone Oxidoreductase
11.2.2.4	NADH Oxidase(s), 324	10.2.8	GSH, 323
11.2.2.5	Cyt c, 325	10.2.9	Dietary Antioxidants in the Brain, 328
11.2.2.6	NOSs, 325	10.3	DNA Repair, 328
11.2.2.7	Nitrate/Nitrite Reductase(s), 326	10.3.1	Alar, 323
11.3	Modulation of Substrates, Metabolites, and Cofactors during I-R, 326	10.3.2	Oxoguanine Glycosylase 1 (OGG1) 323
11.3.1	ROS, 326	10.3.3	Cockayne Syndrome B
11.3.2	Hypoxanthine and Xanthine, 326	10.3.4	Breast Cancer 1 (Brca1), 323
11.3.3	NADH, 326	10.3.5	Mitochondrial Regulation of Protective Responses, 323
11.3.4	BH ₄ , 327	10.3.6	Overview, 323
11.3.5	NO, 327	10.3.7	Mechanism of Action of Nrf2, 323
11.3.6	Peroxynitrite (ONOO ⁻), 328	10.3.8	Genetics of Nrf2, 323
11.3.7	Free Amino Acids, 328	10.3.9	Protein Structure of Nrf2, 323
11.4	ROS-Mediated Cellular Communication during I-R, 328	10.3.10	Regulators of Nrf2, 323
11.5	ROS and Cell Death during Ischemia and Reperfusion, 329	10.3.11	Negative Regulation by Kelch-Like Protein 1 (Keap1) 323
11.5.1	Apoptosis, 329	10.3.12	Negative Regulation by Proteasome, 323
11.5.2	Necrosis, 329	10.3.13	Degradation, 323
11.5.3	Autophagy, 329	10.3.14	Regulation of Nrf2 in Nucleus, 323
11.6	Potential Therapeutic Strategies, 330	10.3.15	ARE, 323
11.6.1	Inhibitors of XDH/XO (Allopurinol/Febuxostat), 330	10.3.16	Activators of Nrf2, 323
11.6.2	BH ₄ Supplementation, 330	10.3.17	Nrf2 in Neurotoxicity and CNS Disease, 323
11.6.3	Nitrate/Nitrite Supplementation, 330	10.3.18	Nrf2 Expression, 323
11.6.4	Ischemic Preconditioning (IPC), 331	10.3.19	Nrf2 in Neurodegenerative Diseases, 323
11.6.5	Pharmacological Preconditioning, 331	10.3.20	Nrf2 in Chemically Induced Neurotoxicity, 323
	Summary and Conclusion, 331	10.3.21	Nrf2 in Fetal Brain, 323
	References, 331	10.3.22	Dietary, 323

12 Atherosclerosis: Oxidation Hypothesis 339

Chandrakala Aluganti Narasimhulu, Dmitry Litvinov, Xueting Jiang, Zhaohui Yang, and Sampath Parthasarathy

Overview, 339

- 12.1 Lipid Peroxidation, 339
- 12.2 Oxidation Hypothesis of Atherosclerosis, 340
 - 12.2.1 The Oxidized LDL (Ox-LDL), 340
- 12.3 Animal Models of Atherosclerosis, 341
 - 12.3.1 Human Atherosclerosis and Animal Models, 342
 - 12.3.2 Progression of Human Disease Calcification, 342
 - 12.3.3 Inflammation and Atherosclerosis, 343
- 12.4 Aldehyde Generation from Peroxidized Lipids, 343
 - 12.4.1 The Oxidation of Aldehydes to Carboxylic Acids, 343
 - 12.4.2 Proatherogenic Effects of Aldehydes, 344
 - 12.4.3 AZA: A Lipid Peroxidation-Derived Lipophilic Dicarboxylic Acid, 344
 - 12.4.4 Could Antioxidants Inhibit the Conversion of Aldehydes to Carboxylic Acids?, 344

Summary, 344

Acknowledgments, 345

References, 345

13 Cystic Fibrosis**355***Neil S. Gould and Brian J. Day*

Overview, 355

13.1 Lung Disease Characteristics in CF, 355

13.1.1 Lung Epithelial Lining Fluid (ELF), Host Defense, and CFTR, 356

13.1.2 Lung Infection and Reactive Oxygen Species (ROS) in CF, 356

13.1.3 Inflammation in CF, 357

13.1.4 Airway Antioxidants in CF, 357

13.2 Role of CFTR in the Lung, 358

13.2.1 Chloride Transport, 358

13.2.2 GSH Transport, 358

13.2.3 SCN Transport, 358

13.3 Oxidative Stress in the CFTR-Deficient Lung, 358

13.3.1 The Importance of ELF Redox Status, 359

13.3.2 Cellular Oxidative Stress, 359

13.3.3 NO and CF, 359

13.3.4 Oxidative Stress Due to Persistent Lung Infection, 359

13.4 Antioxidant Therapies for CF, 361

13.4.1 Hypertonic Saline Inhalation, 361

13.4.2 Pharmacologic Intervention, 361

13.4.3 Oral Antioxidants, 362

13.4.4 Inhaled Antioxidants, 362

Summary, 363

References, 363

14 Cigarette Smoking and Air Pollution**369***Andrew J. Ghio and Urmila Kodavanti***14.1 Exposure to Cigarette Smoke, 369**

14.1.1 Oxidants and Cigarette Smoke Exposure, 369

14.1.2 Oxidative Stress and Disease After Cigarette Smoke Exposure, 370

14.1.3 Oxidative Stress and Mechanistic Pathways of Disease After Cigarette Smoke Exposure, 371

14.2 Air Pollution Particles, 371**14.3 Ozone, 374****14.4 Nitrogen and Sulfur Oxides, 374****14.5 Interaction between PM and Oxidant Gases, 375****14.6 Oxidative Stress and Mechanistic Pathways of Disease After Exposure to Air Pollutants, 375**

References, 375

15 Oxidative Stress in Chronic Obstructive Pulmonary Disease**381***Peter J. Barnes***15.1 Introduction, 381**

15.1.1 Risk Factors and Oxidative Stress, 381

15.1.2 Inflammation in COPD, 381

15.2 Increased Oxidative Stress in COPD, 382

15.2.1 Exogenous Oxidative Stress, 382

15.2.2 Endogenous Oxidative Stress, 383

15.2.3 Generation of Endogenous ROS, 383

- 15.2.4 Measuring Oxidative Stress in COPD, 383
- 15.2.5 Reduction in Antioxidants, 383
- 15.2.6 Iron Overload, 384
- 15.3 Effects of Oxidative Stress in COPD, 384
 - 15.3.1 Increased Inflammation, 384
 - 15.3.2 Corticosteroid Resistance, 384
 - 15.3.3 Accelerated Lung Aging and Cellular Senescence, 385
 - 15.3.4 Autoimmunity, 385
 - 15.3.5 DNA Damage, 386
 - 15.3.6 Mucus Secretion, 386
- 15.4 Strategies for Reducing Oxidative Stress, 386
 - 15.4.1 Dietary Antioxidants, 387
 - 15.4.2 Thiol-based Antioxidants, 387
 - 15.4.3 Antioxidant Mimetics, 387
 - 15.4.4 NOX Inhibitors 387
 - 15.4.5 Peroxidase Inhibitors 388
 - 15.4.6 Inhibiting Nitrate Stress 388
 - 15.4.7 Mitochondria-targeted Antioxidants 388
 - 15.4.8 Nrf2 Activators 388
- 15.5 Conclusions 389
- References, 389

16 Oxidative Stress in the Eye

395

Annie K. Ryan, Wade W. Rich, Peter A. Jansen, Megan M. Allyn,
Katelyn E. Swindle-Reilly, and Matthew A. Reilly

- 16.1 Introduction, 395
- 16.2 The Cornea, 396
 - 16.2.1 Under Physiological Normal Conditions, 396
 - 16.2.2 Diseased States, 398
 - 16.2.2.1 Dry Eye Disease (DED) 398
 - 16.2.2.2 Fuchs Endothelial Corneal Dystrophy (FECD) 398
 - 16.2.2.3 Glaucoma 399
 - 16.2.2.4 Keratoconus 399
- 16.3 The Lens, 400
 - 16.3.1 In Healthy Conditions, 400
 - 16.3.2 Diseased States, 401
 - 16.3.2.1 Cataract 401
 - 16.3.2.2 Presbyopia 402
 - 16.3.2.3 Surgical Aggravation ROS Accumulation 403
- 16.4 The Vitreous Humor, 403
- 16.5 The Retina and Optic Nerve, 404
 - 16.5.1 ROS Sources in Physiologically Normal Conditions, 404
 - 16.5.2 Sources of ROS in the Diseased State, 405
 - 16.5.2.1 Diabetic Retinopathy (DR), 405
 - 16.5.2.2 Aging Retina, 406
 - 16.5.2.3 Traumatic Ocular Injury, 406
 - 16.5.2.4 Leber's Hereditary Optic Neuropathy (LHON), 406
 - 16.5.2.5 Exogenous Therapeutics, 406
- 16.6 Therapeutic Approaches to ROS Elevation in the Eye, 407
 - 16.6.1 Tauroursodeoxycholic Acid (TUDCA), 407
 - 16.6.2 Ibudilast, 407
 - 16.6.3 Mitochondrial Transfer, 407
 - 16.6.4 Oxidative Stress Responsive Particles for Therapeutic Delivery, 407

- 16.6.5 ROS Reduction in the Lens, 407
- 16.6.6 ROS Reduction in the Cornea, 408
- 16.7 Conclusion, 408
- References, 408

17 The Role of Oxidative Stress in Chronic Kidney Disease (CKD) 417

Ara Aboolian, Jordan Younes, Alejandra Romero, Jay C. Jha, Karin Jandeleit-Dahm, and Jaroslawna Meister

- 17.1 Introduction, 417
 - 17.1.1 Definition, 417
 - 17.1.2 Causes of CKD, 418
 - 17.1.3 Diabetes and Hypertension, 419
 - 17.1.4 Glomerulonephritis, 419
- 17.2 Sources of Oxidative Stress in CKD, 419
 - 17.2.1 Mitochondrial ROS in CKD, 420
 - 17.2.2 NADPH Oxidases, 420
 - 17.2.3 Cytochrome P450, 421
 - 17.2.4 Xanthine Oxidase, 421
 - 17.2.5 Nitric Oxide Synthase, 421
- 17.3 Mechanisms by Which Oxidative Stress Contributes to CKD, 421
 - 17.3.1 Inflammation, 422
 - 17.3.2 Fibrosis, 422
- 17.4 Interplay Between Oxidative Stress and Senescence in CKD, 423
 - 17.4.1 Hyperglycemia, 423
 - 17.4.2 Advanced Glycation End Products (AGEs), 423
 - 17.4.3 DNA Damage by Oxidative Stress, 424
 - 17.4.4 Altered Mitochondrial Function and Increased RS Formation, 424
 - 17.4.5 NADPH Oxidase Activation and Senescence, 424
 - 17.4.6 Cyclooxygenases, 424
 - 17.4.7 The Renin–Angiotensin Aldosterone System (RAAS), 425
 - 17.4.8 Hyperphosphatemia, 425
- 17.5 Treatment Options for CKD, 423
 - 17.5.1 RAAS Inhibition, 425
 - 17.5.2 SGLT2 Inhibition, 425
 - 17.5.3 GLP-1 Receptor Agonists and DPP-4 Inhibitors, 427
 - 17.5.4 Antioxidative Therapies, 427
 - 17.5.5 Xanthine Oxidase Inhibition, 427
 - 17.5.6 NOX1/4 Inhibition, 428
 - 17.5.7 Targeting Mitochondrial RS, 428
 - 17.5.8 Therapeutic Strategies Targeting Cellular Senescence, 428
- References, 429

18 Biomarkers of Oxidative Stress in Neurodegenerative Diseases 437

Rukhsana Sultana, Giovanna Cenini, and D. Allan Butterfield

- Overview, 437
- 18.1 Introduction, 437
- 18.2 Biomarkers of Protein Oxidation/Nitration, 439
 - 18.2.1 Protein Carbonyls, 439
 - 18.2.2 Protein Nitration, 440
- 18.3 Biomarkers of Lipid Peroxidation, 441
- 18.4 Biomarkers of Carbohydrate Oxidation, 444

- 18.5 Biomarkers of Nucleic Acid Oxidation, 445
- Acknowledgments, 446
- References, 446

19 Cysteinylated Albumin as Oxidative Stress Biomarker and Therapeutic Target 455

Alessandra Altomare, Giulio Vistoli, Cristina Banfi, and Giancarlo Aldini

- 19.1 Introduction, 455
- 19.2 Cellular and Extracellular Thiols Distribution, 455
- 19.3 HSA and CYS34, 456
- 19.4 CYS34 Reactivity and Reactions, 458
- 19.5 CYS34 Oxidized Forms in Physio-Pathological Conditions, 460
 - 19.5.1 HSA Oxidative State and Chronic Kidney Disease, 460
 - 19.5.2 HSA in Cardiovascular Diseases, 461
- 19.6 Endogenous Regulation of Intracellular and Extracellular Thiol-Redox Homeostasis, 462
- 19.7 Molecular and Therapeutic Strategies for Reversing Mercaptalbumin from the Oxidized Forms, 462
 - 19.7.1 HSA-SH Restore from HNA-1, 463
 - 19.7.2 Functional Effects of HSA-SH, 463
- 19.8 Conclusion, 464
- References, 465

20 Nitroalkene Fatty Acids: Formation, Metabolism, Reactivity, and Signaling 469

Martina Steglich, Martín Sosa, Francisco J. Schopfer, and Lucía Turell

- 20.1 Introduction, 469
- 20.2 Diet and Fatty Acids, 469
- 20.3 Nitroalkene Fatty Acids *in Vivo* Formation, 470
- 20.4 Metabolism and Distribution, 471
- 20.5 Reactivity of Nitroalkene Fatty Acids, 472
- 20.6 Nitroalkylation as A Protein Post-Translational Modification, 473
 - 20.6.1 Kelch-like ECH-Associated Protein 1 (Keap1) and Nuclear Factor (Erythroid-Derived-2)-like2 (Nrf2) activation, 473
 - 20.6.2 Heat-shock Response (HSR) Induction, 474
 - 20.6.3 Nuclear Factor- κ B(NF- κ B) Inhibition, 474
 - 20.6.4 Peroxisome Proliferator-activated Receptor γ (PPAR γ), 474
 - 20.6.5 Other Modified Proteins, 475
- 20.7 Nitrooleic Acid and Disease, 475
- 20.8 Concluding Remarks, 477
- Abbreviations, 477
- References, 478

21 Synthetic Antioxidants 483

Grégory Durand

- Overview, 483
- 21.1 Endogenous Enzymatic System of Defense, 483
- 21.2 Metal-Based Synthetic Antioxidants, 484
 - 21.2.1 Mn^{III} Complexes (Salens), 485
 - 21.2.2 Mn^{III} (Porphyrinato) Complexes (Also Called Metalloporphyrins), 486
 - 21.2.3 Other Metal Complexes, 488

- 21.3 Nonmetal-Based Antioxidants, 488**
- 21.3.1 Ebselen, 488
 - 21.3.2 Edaravone, 491
 - 21.3.3 Lazaroids, 494
- 21.4 Nitrones, 495**
- 21.4.1 Protective Effects of Nitrones (with Particular Attention to PBN), 498
 - 21.4.1.1 Protection against Endotoxic Shock, 498
 - 21.4.1.2 Protection against Diabetes-Induced Damages, 498
 - 21.4.1.3 Protection against Xenobiotic-Induced Damages, 498
 - 21.4.1.4 Protection against Noise-Induced Hearing Loss, 498
 - 21.4.1.5 Protection against Light-Induced Retinal Degeneration, 498
 - 21.4.1.6 Protection against Fulminant Hepatitis, 499
 - 21.4.1.7 Cardioprotective Effects, 500
 - 21.4.2 Antiaging Effects of Nitrones, 500
 - 21.4.3 Neuroprotective Effects of Nitrones, 500
 - 21.4.4 Clinical Development of the Disulfonyl Nitrone, NXY-059, 501
 - 21.4.5 The Controversial Mode of Action of Nitrones, 502
 - 21.4.5.1 Antioxidant Property of PBN against Lipid Peroxydation, 502
 - 21.4.5.2 Anti-Inflammatory and Anti-Apoptotic Properties of Nitrones, 502
 - 21.4.5.3 Action on Membrane Enzymes, 503
 - 21.4.5.4 Interaction with the Mitochondrial Metabolism, 503

References, 504

Index

513

Dr. Parvula Akmal is full professor at the University of Hyderabad, India. He has held various roles within international organizations such as the European Society of Free Radical Research and the HNB international group. He has served as the director of the PhD school in pharmaceutical sciences at the University of Milan. His primary research interest lies in the development and application of high-resolution mass spectrometric techniques in drug discovery and development, with a particular focus on oxidative stress as a drug target and molecular approaches for its prevention. He has authored more than 250 papers.

Dr. Allen Butterfield was born in Maine. He obtained his PhD in physical chemistry from Duke University, followed by a NIH postdoctoral fellowship in Neurosciences at the Duke University School of Medicine. He then joined the Department of Chemistry at the University of Kentucky in 1975, rising to full professor in eight years. He is now the UK Alumni Association endowed professor of Biological Chemistry, director of the Center for Membrane Science, and one of the Basic Biology in Cancer Core of the UK Markey

Cancer Center and faculty of the Sanders-Brown Center for the University of Kentucky. He has published more than 550 refereed papers on his principal research interests in all phases of Alzheimer disease and in mechanisms of chemotherapy-induced cognitive dysfunction (referred to by patients as "chemobrain"). This chapter contribution was co-authored by Rukhsana Sultana and Giovanna Cenini. Dr. Rukhsana Sultana received her PhD in life sciences from the University of Hyderabad. After spending time as a postdoctoral scholar and research associate in the Butterfield laboratory, Dr. Sultana is now a research assistant professor of biological chemistry at the University of Kentucky. She has co-authored more than 100 refereed scientific papers most on oxidative stress in Alzheimer disease. Dr. Giovanna Cenini received her PhD in pharmacology from the University of Brescia in Italy. After spending two years in the Butterfield laboratory as a predoctoral fellow and two years as a postdoctoral scholar, Dr. Cenini is now a postdoctoral scholar in biochemistry at the University of Bonn. She has published approximately 15 papers from her time in the Butterfield laboratory mostly on oxidative stress and p38 in Alzheimer disease and Down syndrome.

Megan M. Aliya, MS, is a PhD candidate in chemical and biomolecular engineering at The Ohio State University. They received dual BS in chemistry and chemical engineering from Kettering University in Flint, MI. Current research includes the development of polymeric drug delivery devices and their investigation for treatment of retinal diseases.